Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|November 19, 2005
Foundation of the European CRO Federation (EUCROF)
At Amsterdam Airport delegates representing the local CRO associations from the Netherlands, Germany, Czech Republic, France, Spain, Italy and United Kingdom were represented for the inaugural meeting of the European CRO Federation (EUCROF).
Advertisement
On Wednesday 19 October 2005 the European CRO Federation was founded.
At Amsterdam Airport delegates representing the local CRO associations from the Netherlands, Germany, Czech Republic, France, Spain, Italy and United Kingdom were represented for the inaugural meeting of the European CRO Federation (EUCROF).
The aims and objectives of EUCROF were defined as:
- Promote the European Union for clinical research.
- Harmonise and actively promote the highest quality standards of clinical research.
- Focussing their strengths to bring more productive discussions with European bodies (EMEA/EU Parliament/Commission).
- Exchange of information between the members.
- Propose thematic discussions with Pharmaceutical Industry representatives e.g. PCMG (Pharmaceutical Contract Management Group) to enhance business relations and identify common causes.
- Develop transcontinental relationships with other Associations, eg ACRO (USA), JCROA (Japan).
The first elected President of EUCROF is Mr. Pieter Guelen from ACRON (The Netherlands). As Vice-President Mrs. Dagmar Chase from BVMA (Germany) was elected. Mr. Dominique Gerbet from AFCROs (France) was elected as treasurer and Mr. Jos Garcia from AECIC (Spain) was elected as general board member. The Federation will be established in the Netherlands.
Members of EUCROF are national associations of Clinical Research Organisations (CROs). The current 7 associations are representative of the local CROs network and represent as of today 250 companies.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5